BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT) an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, was recently featured on Uptick Newswire’s Stock Day Podcast. Dr. Bill Williams, BriaCell’s president and CEO, was interviewed for the podcast by Everett Jolly of Stock Day. Per the interview, Dr. Williams expressed his enthusiasm regarding the company’s future, as he believes BriaCell is on the cutting edge of cancer treatment with its effective and safe immunotherapy applications. Williams also detailed BriaCell’s current major programs: Bria-IMT, which is in the clinic right now, and Bria-OTS, which is in development. “BriaCell is developing the first off-the-shelf, personalized immunotherapy targeting advanced breast cancer,” Dr. Bill Williams, BriaCell’s president and CEO, stated during the interview. “We have a proprietary technology that allows us to target immune responses in breast cancer in a personalized fashion. (The solution) we are working towards is an off-the-shelf immunotherapy which is very similar in some ways to other successful targeted personalized immunotherapies that are not off-the-shelf, are costly, and have been associated with complex manufacturing.”
To listen to the full interview, visit http://ibn.fm/USaQm
To view the full press release, visit http://ibn.fm/2mwWQ
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
